Candel Therapeutics, Inc. (CADL) is a Biotechnology company in the Healthcare sector, currently trading at $5.10. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is CADL = $15 (+194.1% upside).
Valuation: CADL trades at a trailing Price-to-Earnings (P/E) of -7.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.16.
Net income is $38M (loss), growing at -412.8%/yr. Net profit margin is 0% (thin). Gross margin is -689.6% (+0 pp trend).
Balance sheet: total debt is $2M against $52M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 13.31 (strong liquidity). Debt-to-assets is 1.5%. Total assets: $125M.
Analyst outlook: 9 / 10 analysts rate CADL as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 11/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
